Dr Jennifer Batson will present ‘A Paradigm Shift in the Treatment of Retinal Vascular Diseases’ at Pharmacology 2017 on Tuesday 12 December 2017 Exonate is developing eye drops to revolutionise current standard-of-care in the treatment of eye diseases Cambridge, UK – 11 December 2017: Exonate an early stage biotechnology company, today announces that its principal…Details
Wellcome – 10 ideas we fund that might surprise you. From eyeball injections to eye drops for sight loss
November 2017 Wellcome – 10 ideas we fund that might surprise you From eyeball injections to eye drops for sight loss In September this year, Exonate welcomed a film crew from Wellcome Trust to the labs in Nottingham. Wellcome Trust were making a series of short 1-minute films to share on Facebook, Twitter@wellcometrust and the…Details
Exonate announces the formation of ophthalmology Clinical Advisory Board (“Exonate” or the “Company”)
Ophthalmology leaders to support early stage biotechnology company with potential to revolutionise current standard-of-care in the treatment of eye diseases Cambridge, UK – 8 November: Exonate, an early stage biotechnology company, today announces the formation of its Clinical Advisory Board (CAB) to support the scientific, pre-clinical development of a revolutionary eye-drop treatment for retinal…Details
Exonate is the ‘One to Watch’ in the Best Investment in Life Sciences Exonate Limited were awarded the ‘One to Watch’ at the UK Business Angels Association Investment Awards last night. The judges said: ‘Exonate is showing promise in developing revolutionary approaches to treatments for…Details
Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)
Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need Cambridge, UK. Monday 6th February 2017 – Exonate, an early stage biotechnology company has been awarded a £4.9m Seeding Drug Discovery award by the Wellcome Trust to continue development of an eye – drop treatment for wet age–related macular degeneration. …Details
Exonate closes successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD)
Exonate closes successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD) New and existing investors participated in the round Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need Cambridge, UK. Wednesday [30th] November 2016 – Exonate, an early stage biotechnology company, today announced they…Details
Jenny Batson was awarded the David Meyer research prize for the best presentation at the Nottingham Eye Symposium 20th Annual Meeting 2016.Details
Scientists have worked out how to stop tumours growing in a breakthrough which could switch off many cancers and even prevent blindness.
Cambridge UK life science entrepreneur Dr Catherine Beech is spearheading a truly international startup initially targeting eye disease but with applications in cancer and other disease areas.
The ideas were all conceived by scientists in Nottingham – one about blood and two about eyes. And all have found potential financial backers after presentations to the newly-formed Nottingham Angels Network.
EXONATE is the brainchild of David Bates, a professor of oncology at the QMC. Prof Bates believes he can develop molecule-based eye drops, making the once-a-month injections unnecessary for wet age-related macular degeneration, the commonest form of blindness in the western world, with 30 million sufferers worldwide.Details
University of Nottingham spin-out business, Exonate, which specialises in the discovery and development of novel drugs, has received funding of over £400,000 from Fusion IP PLC, IP Group PLC, The University of Nottingham and a syndicate of business angels, including the newly formed Nottingham Angels Network.